$LQDA

We’re thrilled to release this week’s special episode of our podcast, an interview with not one, but two wonderful guests: Steven Kiel and Viral Kothari. Our conversation with @Steven_Kiel and @CFAs4CFPs centered around the case for Liquidia $LQDA, a biotech company embroiled in a legal struggle with United Therapeutics $UTHR. We covered the commercial stage and Phase 3 drugs that Liquidia currently markets or is developing, the various legal cases between United Therapeutics and Liquidia, the broader PAH and PH-ILD addressable markets (the disease space in which Liquidia operates), and so much more. This was a deep dive into a unique legal special situation, and we hope our listeners enjoy this as much as we enjoyed recording it!